Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 8131 to 8145 of 8939 results

  1. Savolitinib for treating MET-driven unresectable advanced papillary renal cell carcinoma [ID1638]

    Discontinued Reference number: GID-TA10634

    Technology appraisal guidance
    Discontinued

  2. Niraparib for previously treated hormone-relapsed metastatic prostate cancer with DNA-repair anomalies [ID3782]

    Discontinued Reference number: GID-TA10635

    Technology appraisal guidance
    Discontinued

  3. Eryaspase with chemotherapy for previously treated advanced or metastatic pancreatic cancer [ID3781]

    Discontinued Reference number: GID-TA10637

    Technology appraisal guidance
    Discontinued

  4. Ticagrelor for preventing stroke after previous ischaemic stroke or high-risk transient ischaemic attack [ID2689]

    Discontinued Reference number: GID-TA10663

    Technology appraisal guidance
    Discontinued

  5. Autologous chondrocyte implantation using 3D collagen matrix (novocart 3D) for treating articular cartilage defects of the knee [ID2707]

    In development Reference number: GID-TA10667 Expected publication date: TBC

    Technology appraisal guidance
    In development

  6. Pembrolizumab with docetaxel for treating hormone-relapsed metastatic prostate cancer untreated with chemotherapy [ID3801]

    Discontinued Reference number: GID-TA10668

    Technology appraisal guidance
    Discontinued

  7. Pelareorep for treating metastatic malignant melanoma after previous therapy [ID941]

    Discontinued Reference number: GID-TA10686

    Technology appraisal guidance
    Discontinued

  8. Pelareorep for treating relapsed or refractory multiple myeloma [ID1028]

    Discontinued Reference number: GID-TA10687

    Technology appraisal guidance
    Discontinued

  9. Pelareorep for treating recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal cancer [ID1099]

    Discontinued Reference number: GID-TA10688

    Technology appraisal guidance
    Discontinued

  10. Pelareorep for untreated pancreatic cancer [ID1074]

    Discontinued Reference number: GID-TA10689

    Technology appraisal guidance
    Discontinued

  11. Heart failure (acute decompensated) - nesiritide [ID384]

    Discontinued Reference number: GID-TAG376

    Technology appraisal guidance
    Discontinued

  12. Atrial fibrillation - ximelagatran [ID376]

    Discontinued Reference number: GID-TAG377

    Technology appraisal guidance
    Discontinued

  13. Venous thromboembolism (VTE) - ximelagatran [ID396]

    Discontinued Reference number: GID-TAG378

    Technology appraisal guidance
    Discontinued

  14. Prostate cancer (hormone refractory) - atrasentan [ID390]

    Discontinued Reference number: GID-TAG379

    Technology appraisal guidance
    Discontinued

  15. Drugs for the treatment of pulmonary arterial hypertension [ID12]

    Discontinued Reference number: GID-TAG382

    Technology appraisal guidance
    Discontinued